Cleland J L, Powell M F, Shire S J
Genentech, Inc., South San Francisco, CA 94080.
Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77.
The biochemical literature has been surveyed to present an overview of the three most common protein degradation pathways: protein aggregation, deamidation, and oxidation. The mechanisms for each of these degradation routes are discussed with particular attention given to the effect of formulation conditions such as pH, ionic strength, temperature, and buffer composition. Strategies to reduce protein degradation are also discussed. These strategies are based on an understanding of the degradation mechanisms and the effect of changes in the storage conditions and formulation components on the degradation. The effects of each of the degradation routes on pharmaceutically relevant properties such as biological activity, metabolic half-life, and immunogenicity are summarized. Predicting a priori the alteration of pharmaceutical properties caused by the three degradation routes is difficult, and must be determined on a case-by-case basis for each protein. The difficulty in predicting the effect of degradation and analyzing the temperature dependence of reaction rates in proteins results in longer development times for protein formulations than for small molecule formulations. Although the use of accelerated stability to predict protein shelf life is difficult, conditions are discussed whereby the Arrhenius equation can be used to shorten formulation development time.
我们对生化文献进行了调研,以概述三种最常见的蛋白质降解途径:蛋白质聚集、脱酰胺和氧化。文中讨论了每种降解途径的机制,并特别关注了诸如pH值、离子强度、温度和缓冲液组成等制剂条件的影响。还讨论了减少蛋白质降解的策略。这些策略基于对降解机制以及储存条件和制剂成分变化对降解影响的理解。总结了每种降解途径对生物活性、代谢半衰期和免疫原性等药学相关性质的影响。事先预测由这三种降解途径引起的药物性质变化是困难的,必须针对每种蛋白质逐案确定。预测降解影响和分析蛋白质中反应速率的温度依赖性存在困难,这导致蛋白质制剂的研发时间比小分子制剂更长。尽管利用加速稳定性来预测蛋白质保质期很困难,但文中讨论了可使用阿伦尼乌斯方程来缩短制剂研发时间的条件。